Literature DB >> 8485327

Leucine and manifestation of antitumor activity by valine-depleted amino acid imbalance.

T Nishihira1, T Takagi, S Mori.   

Abstract

With a commercially available balanced 10% amino acid solution as control (I), imbalance solutions were prepared by the removal of valine (II), valine and leucine (III), valine and isoleucine (IV), and valine, leucine, and isoleucine (V). The solutions, in combination with total parenteral nutrition, were given to rats with AH-109A hepatoma for 7 consecutive days to evaluate antitumor activity. Although there were no significant differences in carcass weight after treatment among groups I-IV, a decrease was noted in group V. Tumor weights in groups II-V, relative to that in group I, were 39, 57, 43, and 44%, respectively. Antitumor activity was thus noted in all imbalance groups, although activity in group III was lower than that in group II. These results indicate that the concurrent depletion of leucine and/or isoleucine along with valine is undesirable because of lower antitumor activity and an adverse effect on host development. Leucine is thus suggested to play an important role in augmenting the activity of valine-depleted imbalance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485327

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  3 in total

1.  Influence of methionine/valine-depleted enteral nutrition on nucleic acid and protein metabolism in tumor-bearing rats.

Authors:  Yin-Cheng He; Jun Cao; Ji-Wei Chen; Ding-Yu Pan; Ya-Kui Zhou
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Influence of L-methionine-deprived total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism.

Authors:  H B Xiao; W X Cao; H R Yin; Y Z Lin; S H Ye
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Adjuvant therapies for cancer of the thoracic esophagus.

Authors:  T Nishihira; T Nakano; S Mori
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.